Platform FateAI: Development of DNA methylation-based tests for early diagnosis and prognostic definition of tumor lesions from liquid biopsy. The FateAI E Line is designed for the early identification and

ONCO-ND1 Platform: Immunological characterization of tumor samples for the identification of markers for response to immunotherapies. ONCO-ND1 line. As for the ONCO-ND1 line, the use of immune checkpoint inhibitors has